Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 7/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 9/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612088 | 0.89 | ENPP1 (0.49) | ENPP1MBOAT4HTTSMN1; SMN2GAA | |
| SCHEMBL3630090 | 0.78 | ALDH1A1 (0.46) | ENPP1MBOAT4 | |
| SCHEMBL610632 | 0.78 | MBOAT4 (0.43) | ENPP1MBOAT4GAADHFR | |
| SCHEMBL607989 | 0.78 | MBOAT4 (0.43) | ENPP1MBOAT4GAADHFR | |
| SCHEMBL612481 | 0.78 | MBOAT4 (0.43) | ENPP1MBOAT4GAADHFR | |
| SCHEMBL3632479 | 0.77 | MBOAT4 (0.42) | ENPP1MBOAT4GAA | |
| SCHEMBL611053 | 0.77 | TSHR (0.40) | ENPP1MBOAT4 | |
| SCHEMBL611382 | 0.77 | MBOAT4 (0.42) | ENPP1MBOAT4 | |
| SCHEMBL11889953 | 0.76 | MBOAT4 (0.42) | MBOAT4 | |
| SCHEMBL611395 | 0.76 | MBOAT4 (0.41) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557828-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-10-15 | — | — | US | claimed |
| EP-2142552-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | claimed |
| US-20120041003-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | claimed |
| US-8076344-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | claimed |
| EP-2142552-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | claimed |
| US-20080293713-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-11-27 | — | — | US | claimed |
| WO-2008134690-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | claimed |
| US-8557828-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2500347-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | Abbott Laboratories (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2142552-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120041003-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076344-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2142552-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080293713-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008134690-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041003-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | ENPP1 270/4885MBOAT4 69/4885HTT 2049/4885 |
| US-20080293713-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | DGAT1, DGAT2, LCAT | ENPP1 270/4885MBOAT4 69/4885HTT 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.